Paul Hastings, Nkarta CEO and BIO chair
May 10, 2022 10:43 AM EDT
People

'Front and cen­ter': In­dus­try lead­ers call for re­sponse to Supreme Court abor­tion case draft

Kyle LaHucik

Senior Reporter

Biotech in­dus­try lead­ers want the drug de­vel­op­ment world to stand up and en­sure em­ploy­ees have ac­cess to abor­tions af­ter a draft rul­ing last week re­vealed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times